Skip to content

Rising Prevalence of Metabolic Dysfunction - Associated Steatotic Liver Disease in an urban South Indian screening cohort: a Retrospective Cross-sectional Study.

Nov 2026 · Annals of Epidemiology · Vol 124, pp. 110309 · 0 citations · 20 references
Medicine

TL;DR

Nearly two-thirds of asymptomatic urban South Indian adults screened met MASLD criteria, predominantly working-age individuals under-detected by conventional tools, suggesting FibroScan-based screening should be considered in preventive health programmes to enable earlier detection.

Abstract

Purpose

Metabolic dysfunction-associated steatotic liver disease (MASLD), redefined in 2023 from non-alcoholic fatty liver disease, is highly prevalent globally, but population-level data using 2023 AASLD criteria and FibroScan-based assessment remain scarce in South Asia, particularly among asymptomatic adults undergoing routine health screening.

Methods

We conducted a retrospective cross-sectional study of 1,103 asymptomatic adults (mean age 43.1±12.7 years; 64.1% male) undergoing FibroScan-based Master Health Check-up at a tertiary centre in Chennai, India (2023-2025). MASLD was defined as controlled attenuation parameter (CAP) ≥249 dB/m plus ≥1 cardiometabolic risk factor; fibrosis was assessed by liver stiffness measurement (LSM).

Results

MASLD was identified in 716 participants (64.9%; 95% CI 62.1-67.7%). Affected individuals were older, had higher BMI, and more frequently had diabetes, hypertension, and dyslipidaemia (all p<0.01). In multivariable analysis, age, male sex, BMI, and diabetes were independently associated with MASLD. Notably, 53.4% of cases occurred in adults under 46 years, and 45.3% had normal liver function tests while 31.3% had normal ultrasound, indicating conventional screening substantially underestimates disease burden.

Conclusions

Nearly two-thirds of asymptomatic urban South Indian adults screened met MASLD criteria, predominantly working-age individuals under-detected by conventional tools. FibroScan-based screening should be considered in preventive health programmes to enable earlier detection.

View source

Similar papers

Open access Oct 2026

Sex differences in the prevalence of metabolic dysfunction-associated steatotic liver disease in hospitalized patients: a single-center cross-sectional study

Background The influence of sex and age on the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) among hospitalized patients remains unclear. Methods This cross-sectional study included 136,816 hospitalized adults (2014–2023) at the People’s Hospital of Guangxi Zhuang Autonomous Region. Hep...

Zhe-Min Liu, Suo-Su Wei · 0 citations
Review Open access Oct 2026

Association between metabolic dysfunction-associated steatotic liver disease and atherosclerotic cardiovascular disease in a tertiary care hospital: A cross-sectional study

Obesity, diabetes, and metabolic syndrome are becoming increasingly prevalent in Saudi Arabia, and therefore, raising concerns about metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic steatohepatitis (MASH), and related cardiovascular complications. This study compared the occurrence of a...

Reem K. AlManea, Kossay El-Abd, Sara H. Alsinan et al. · 0 citations
Open access Oct 2026

Screening for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes patients using the fibrosis-4 score in medina-retrospective study

The findings endorse the need for screening for liver fibrosis in T2DM patients, particularly those at increased risk, and suggest early detection and appropriate management are essential to prevent progression to advanced liver disease.

M. Almohammadi, Z. E. Alsadi, A. B. Alenezi et al. · 0 citations
Open access 2025

Screening for metabolic dysfunction-associated steatotic liver disease related advanced fibrosis in diabetology: a prospective multi-center study.

Objective: Screening for advanced fibrosis (AF) due to metabolic dysfunction-associated steatotic liver disease (MASLD) is recommended in diabetology. This study aimed to compare the performance of non-invasive tests (NITs) and 2-step algorithms for detecting patients with high-risk AF requiring referral to hepatologis...

C. Caussy, B. Vergès, Damien Leleu et al. · 0 citations
Review Oct 2026

Serum Uric Acid and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Two-Stage NHANES Study of MASLD Prevalence and All-Cause Mortality.

BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing public health challenge, highlighting the need for accessible markers of metabolic liver disease risk. Serum uric acid (SUA) has been linked to metabolic dysfunction, but its association with MASLD across the full clinical spectrum...

Hafiz M. Ahmed, Umm E. Aimen · 0 citations
Open access Oct 2026

Type 1 Diabetes Mellitus And Metabolic Dysfunction-Associated Steatotic Liver Disease In Children And Adolescents: A Cross-Sectional Study.

Adiposity-related parameters and dyslipidemia appear to be important clinical features associated with hepatic steatosis in pediatric T1DM, which had a higher prevalence of CAP-based hepatic steatosis/MASLD than healthy controls.

Hanife Ayşegül Arsoy, Ö. Kara, Murat Keskin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.